The purpose of this study is to evaluate the safety and preliminary effectiveness of a new vaccine designed to train the immune system to recognize and fight ovarian, fallopian tube, or peritoneal cancer cells. The vaccine is being assessed in patients with these cancers who have achieved a first remission and have a high risk of cancer recurrence. Investigators will assess various doses of the vaccine.
The vaccine in this study contains antigens or “fingerprints” that are found on many cancer cells, especially those from the ovaries, fallopian tubes, or peritoneal cavity (inside lining of the abdomen). The antigens in this vaccine are called Globo-H, GM2, sTn, TF, and Tn. They have been assessed in patients individually; this is the first time all of the antigens have been put together on a single molecule and evaluated in patients.
The antigens are given with a material called QS-21, which may help the immune system to make more cancer-fighting cells. The group of antigens is attached to a material called keyhole limpet hemocyanin (KLH), which has been used for many years to boost the immune system in laboratory animals and in people.